Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
After football on WRAL: Patchy fog to start the school year. Where your kids will be likely to see it at the bus stop.
Program
On WRAL Monday at 6: Known carcinogens hiding in your childâs classroom? WRAL Investigates why some local schools are refusing to take action
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ultragenyx Pharmaceu
(NQ:
RARE
)
56.75
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ultragenyx Pharmaceu
< Previous
1
2
3
4
5
6
7
8
9
Next >
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 21, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
August 06, 2024
Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
3 Genomics Stocks That May Transform Personalized Medicine
August 06, 2024
These are three of the best genomics stocks to buy for a lucrative entry into a specialized section of the biotech industry.
Via
InvestorPlace
Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
August 01, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical
July 22, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Ultragenyx Pharmaceutical Through Analyst Insights
May 31, 2024
Via
Benzinga
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
July 25, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
July 24, 2024
Presentations will include an encore of the positive interim Phase 1/2 results presented in April at the 76th Annual American Academy of Neurology (AAN) Meeting
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
July 22, 2024
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety...
Via
Benzinga
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
July 22, 2024
Biogen previously decided against opting into Ionis' Angelman program.
Via
Investor's Business Daily
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 19, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
July 17, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 20, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
June 17, 2024
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities.
Via
InvestorPlace
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 14, 2024
Via
Benzinga
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
June 13, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Dave & Buster's Posts Downbeat Results, Joins J.Jill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
June 13, 2024
Via
Benzinga
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 12, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
June 12, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
June 11, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
This United Airlines Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
June 06, 2024
Via
Benzinga
Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
May 30, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells
May 22, 2024
The estate of Henrietta Lacks can proceed with a lawsuit against Ultragenyx Pharmaceutical over the use of HeLa cells taken without her consent in the 1950s. A Maryland federal court ruled against...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
May 07, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
RARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024
May 02, 2024
RARE stock results show that Ultragenyx Pharmaceutical missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
May 02, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
April 30, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
April 30, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.